Danish Pain Research Center, Aarhus University Hospital
Aarhus, 8000, Denmark
NCT Number: NCT00168974
Fabry disease is a rare X-linked lysosomal storage disorder. The mutations result in a deficiency of the lysosomal enzyme α-galactosidase causing accumulation of glycosphingolipids in the vascular endothelial cells and many other tissues. An early sign of the disease is painful small fibre neuropathy presenting in two forms: 1. a constant burning sensation in the hand and feet and 2. Fabry crises consisting of attacks of excruciating pain. Given the X-linked inheritance, male patients are severely affected. Recently attention has been drawn to female patients whether they also show signs of nerve involvement.
The purpose of this study is to evaluate the small fibre neuropathy in female Fabry patients. Correlation with X-chromosome inactivation will be attempted. Recombinant human α-galactosidase A is now available for patients. A part of this study is evaluation the long term efficacy of enzyme replacement therapy in female patients with Fabry disease and neuropathy.
Male family members with Fabry disease will be examined.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Aarhus, 8000, Denmark
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Danish Pain Research Center
Other
Somatosensoric and Autonomic Disturbances in Female Patients With Fabry Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05923788
Brain Diseases, Brain Diseases, Metabolic
Lyon, France
View Trial DetailsNCT03614234
Brain Diseases, Brain Diseases, Metabolic
Birmingham, Alabama, United States
View Trial DetailsNCT04046224
Brain Diseases, Brain Diseases, Metabolic
Irvine, California, United States
View Trial DetailsNCT03566017
Brain Diseases, Brain Diseases, Metabolic
Birmingham, Alabama, United States
View Trial Details